Safety and Efficacy of Sacituzumab Govitecan in the Treatment of HR+/HER2- mBC
September 26th 2023
Virginia Kaklamani, MD, and Elizabeth Diaz, PA-C, Diaz review the available safety and efficacy data from the TROPiCS-02 trial on the use of antibody drug conjugate sacituzumab govitecan for the treatment of HR+/HER2- metastatic breast cancer.